Joint (NASDAQ:JYNT) Receives Buy Rating from Maxim Group

Maxim Group reiterated their buy rating on shares of Joint (NASDAQ:JYNT) in a research report sent to investors on Friday, AnalystRatings.com reports. Maxim Group currently has a $25.00 price objective on the stock.

Other equities analysts have also recently issued reports about the company. B. Riley set a $23.00 price objective on Joint and gave the company a buy rating in a report on Friday, August 9th. Lake Street Capital lifted their price objective on Joint from $20.00 to $30.00 and gave the company a buy rating in a report on Friday, August 9th. DA Davidson reaffirmed a buy rating on shares of Joint in a report on Monday, November 4th. ValuEngine cut Joint from a buy rating to a hold rating in a report on Wednesday, October 2nd. Finally, Zacks Investment Research raised Joint from a hold rating to a buy rating and set a $23.00 price objective for the company in a report on Wednesday, October 30th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Joint currently has an average rating of Buy and a consensus price target of $24.17.

Joint stock traded down $0.66 during midday trading on Friday, reaching $19.15. The stock had a trading volume of 459,700 shares, compared to its average volume of 155,324. The stock has a market capitalization of $275.64 million, a P/E ratio of 478.75 and a beta of 1.01. The company has a debt-to-equity ratio of 3.33, a quick ratio of 1.04 and a current ratio of 1.04. The firm’s fifty day simple moving average is $18.82 and its 200-day simple moving average is $18.09. Joint has a 1-year low of $6.51 and a 1-year high of $21.80.

Joint (NASDAQ:JYNT) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.01. The firm had revenue of $12.73 million during the quarter, compared to analysts’ expectations of $11.60 million. Joint had a return on equity of 114.93% and a net margin of 5.38%. On average, sell-side analysts anticipate that Joint will post 0.2 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Bandera Partners LLC raised its holdings in shares of Joint by 4.6% during the 2nd quarter. Bandera Partners LLC now owns 1,364,301 shares of the company’s stock worth $24,830,000 after buying an additional 60,000 shares in the last quarter. BlackRock Inc. increased its holdings in Joint by 1,224.0% in the 2nd quarter. BlackRock Inc. now owns 769,378 shares of the company’s stock worth $14,002,000 after purchasing an additional 711,267 shares in the last quarter. Skylands Capital LLC increased its holdings in Joint by 4.4% in the 2nd quarter. Skylands Capital LLC now owns 550,701 shares of the company’s stock worth $10,023,000 after purchasing an additional 23,051 shares in the last quarter. Vanguard Group Inc. increased its holdings in Joint by 42.0% in the 2nd quarter. Vanguard Group Inc. now owns 538,070 shares of the company’s stock worth $9,793,000 after purchasing an additional 159,034 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in Joint by 17.3% in the 2nd quarter. Acadian Asset Management LLC now owns 254,919 shares of the company’s stock worth $4,639,000 after purchasing an additional 37,653 shares in the last quarter. 64.45% of the stock is owned by institutional investors.

About Joint

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.

Read More: How are the companies in the S&P 500 selected?

Analyst Recommendations for Joint (NASDAQ:JYNT)

Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.